Inhibitory Nucleic Acids Targeting MiR-33 for Lipid Metabolism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively address elevated triglycerides and associated metabolic disorders such as metabolic syndrome, non-alcoholic fatty liver disease, and type 2 diabetes, as they do not adequately regulate fatty acid and triglyceride homeostasis.
Innovation Solution
Administration of inhibitory nucleic acids complementary to microRNAs 33a and 33b (miR-33a and miR-33b) to target and regulate key proteins involved in fatty acid and triglyceride metabolism, thereby reducing circulating and stored triglycerides and improving metabolic health.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods are used to address elevated triglycerides, then treatment is provided, but fatty acid and triglyceride homeostasis is not adequately regulated
Solution Approach 1:
The patent uses microRNA molecules (specifically miR-33 inhibitors) as intermediary substances that mediate the regulation of fatty acid and triglyceride metabolism. These microRNAs act as molecular mediators that specifically target and regulate key proteins involved in lipid homeostasis, providing reliable and effective control that current methods lack.
Solution Approach 2:
The invention changes the molecular parameter of gene expression regulation by introducing inhibitory microRNAs that specifically bind to target mRNAs (such as SREBP-1c, FAS, ACC1). This parameter change at the molecular level leads to reduced expression of lipogenic enzymes and improved triglyceride homeostasis, directly addressing the inadequacy of current treatment methods.
2Productivity
If inhibitory nucleic acids complementary to miR-33a and miR-33b are administered, then triglyceride levels decrease and metabolic health improves, but the complexity of the treatment approach increases
Solution Approach 1:
The patent extracts and targets specific microRNA molecules (miR-33a and miR-33b) that are identified as key regulators of lipid metabolism. By isolating and inhibiting these specific microRNAs, the treatment achieves high effectiveness in triglyceride reduction while simplifying the approach compared to broad-spectrum metabolic interventions.
Solution Approach 2:
The treatment approach segments the complex metabolic regulation into specific targetable pathways by identifying and inhibiting particular microRNAs (miR-33a, miR-33b) that control multiple downstream genes involved in fatty acid synthesis and triglyceride metabolism. This segmentation allows for precise intervention in lipid homeostasis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively decreases triglyceride levels, ameliorates non-alcoholic fatty liver disease, obesity, and related complications by enhancing mitochondrial fatty acid beta-oxidation and reducing insulin-dependent expression of SREBP-1c, thereby addressing metabolic syndrome and insulin resistance.
Implementation Method 1
administering to the subject a therapeutically effective amount of an inhibitory nucleic acid that is complementary to SEQ ID NOs. 1 or 2
Implementation Method 2
administration of the inhibitory nucleic acid that is complementary to SEQ ID NOs. 1 or 2 increases mitochondrial fatty acid beta-oxidation resulting in reduced levels of stored and circulating triglycerides
Implementation Method 3
administration of the inhibitory nucleic acid that is complementary to SEQ ID NOs. 1 or 2 reduces insulin-dependent expression and function of SREBP-lc, thereby decreasing fatty acid and triglyceride production
Data Source
Figure 1A
Figure 1B~2
Figure 3A~4C
AI summary
Compositions comprising nucleic acid sequences that target MiR-33a/b microRNAs are described, together with uses of the same in the treatment of certain disorders related to elevated serum triglyceride levels and obesity.